Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortCOVID-19 antiviral pills for people at high risk.IV antiviral for COVID-19.
Body systemAntiviralsAntivirals
Drug classViral protease inhibitorsRNA polymerase inhibitors
SupplyPrescription onlyPrescription only
Main usesMild to moderate COVID-19 in people at high risk of severe diseaseCOVID-19 in hospital, Early COVID-19 in high-risk outpatients (3 days)
How it worksBlocks the enzyme the coronavirus uses to cut its proteins into working parts.Slips into the virus's genetic material as it's copied and stops the process.
Starts working——
Half-lifeAbout 6 hoursAbout 1 hour (parent); metabolites longer
Typical adult dose300 mg nirmatrelvir + 100 mg ritonavir twice a day for 5 days, started within 5 days of symptoms (lower dose in moderate kidney disease).200 mg on day 1, then 100 mg daily.
FormsCo-packaged tabletsIV infusion
Common side effectsAltered taste ('Paxlovid mouth'), Diarrhoea, NauseaNausea, Raised liver enzymes
Serious side effectsDangerous interactions with other medicines, Allergic reactionsInfusion reactions, Slow heart rate, Liver injury
Don't take if——
Alcohol——
PregnancyUse with cautionCan be used if benefits outweigh risks; limited data.Use with cautionUsed when benefits outweigh risks.
Breastfeeding——
In use since20212020
Brand namesUnited States: PaxlovidUnited Kingdom: PaxlovidAustralia: PaxlovidUnited States: VekluryUnited Kingdom: VekluryIndia: Covifor, Cipremi
Legal status——
ATC code—J05AB16

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker